Structural analysis of the N-acetyltransferase Eis1 from Mycobacterium abscessus reveals the molecular determinants of its incapacity to modify aminoglycosides
Kien Lam Ung, Laurent Kremer, Mickael Blaise

To cite this version:
Kien Lam Ung, Laurent Kremer, Mickael Blaise. Structural analysis of the N-acetyltransferase Eis1 from Mycobacterium abscessus reveals the molecular determinants of its incapacity to modify aminoglycosides. Proteins - Structure, Function and Bioinformatics, Wiley, 2020, 10.1002/prot.25997. hal-02988304

HAL Id: hal-02988304
https://hal.archives-ouvertes.fr/hal-02988304
Submitted on 5 Nov 2020
Structural analysis of the N-acetyltransferase Eis1 from *Mycobacterium abscessus* reveals the molecular determinants of its incapacity to modify aminoglycosides.

**Running title:** Crystal structure of *M. abscessus* Eis1

Kien Lam Ung¹, Laurent Kremer¹,² and Mickaël Blaise*¹

¹Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS UMR 9004, Montpellier, France.
²INSERM, IRIM, 34293 Montpellier, France.

*Corresponding author:
Tel: (+33)434359447; E-mail: mickael.blaise@irim.cnrs.fr

**Abstract**

Enhanced intracellular survival (Eis) proteins belonging to the superfamily of the GCN5-related *N*-acetyltransferases play important functions in mycobacterial pathogenesis. In *Mycobacterium tuberculosis*, Eis enhances the intracellular survival of the bacilli in macrophages by modulating the host immune response and is capable to chemically modify and inactivate aminoglycosides. In non-tuberculous mycobacteria (NTM), Eis shares similar functions. However, *Mycobacterium abscessus*, a multi-drug resistant NTM, possesses two functionally distinct Eis homologues, Eis1ₘₐᵇ and Eis2ₘₐᵇ. While Eis2ₘₐᵇ participates in virulence and aminoglycosides resistance, this is not the case for Eis1ₘₐᵇ, whose exact biological function remains to be determined. Herein, we show that overexpression of Eis1ₘₐᵇ in *M. abscessus* fails to induce resistance to aminoglycosides. To clarify why Eis1ₘₐᵇ is unable to modify this class of antibiotics, we solved its crystal structure bound to its cofactor, acetyl-CoA. The structure revealed that Eis1ₘₐᵇ has a typical homohexameric Eis-like organization. The structural analysis supported by biochemical approaches demonstrated that while Eis1ₘₐᵇ can acetylate small substrates, its active site is too narrow to accommodate aminoglycosides. Comparison with other Eis structures showed that an extended loop between strands 9 and 10 is blocking the access of large substrates to the active site and movement of helices 4 and 5 reduces the volume of the substrate-binding pocket to these compounds in Eis1ₘₐᵇ. Overall, this study underscores the molecular determinants explaining functional differences between Eis1ₘₐᵇ and Eis2ₘₐᵇ, especially those inherent to their capacity to modify aminoglycosides.
Keywords: *Mycobacterium abscessus*, *N*-acetyltransferase, aminoglycosides, Eis, GCN5, X-ray structure

Introduction

*N*-acetyltransferases are enzymes catalyzing the transfer of acyl groups from acyl-CoA to a wide panel of substrates, ranging from small molecules like spermine to large macromolecules, such as histones. Prokaryotic *N*-acetyltransferases belonging to the GCN5-related *N*-acetyltransferases family (GNAT) are capable to modify a large set of small substrates, including aminoglycoside antibiotics. They can exert pleiotropic effects, participating for instance in the biosynthesis of mycothiol, a mycobacterial antioxidant, or can modify bacterial peptides/proteins as well as host proteins in the case of pathogenic bacteria. The Eis protein was initially discovered to confer enhanced survival of *Mycobacterium smegmatis* in macrophages, hence its designation as Enhanced Intracellular Survival. Numerous studies have subsequently addressed the function of Eis from *Mycobacterium tuberculosis* (Eis\textsubscript{Mtb}) emphasizing its capacity to modulate the host inflammatory response and autophagy as well as its activity to acetylate various proteins, including the host histone H3 and the mycobacterial nucleoid-associated protein HU.

In *M. tuberculosis* clinical strains, mutations in the *eis* promoter resulted in the up-regulation of *eis* expression and resistance to kanamycin. The role of Eis\textsubscript{Mtb} in the modification of aminoglycosides has been the subject of deep biochemical and structural investigations, demonstrating that its belongs to the GNAT superfamily of proteins. Eis\textsubscript{Mtb} forms a homohexamer and can modify a wide range of aminoglycosides through mono- or poly-acetylations of their primary amine groups.

Consistent with these findings, the Eis2 protein (Eis\textsubscript{Mab}) has been shown to also play a key role in *Mycobacterium abscessus*, a non-tuberculous mycobacterium (NTM), recognized as an emerging human pathogen. The *M. abscessus complex* comprises three subspecies, *M. abscessus sensu stricto*, *M. abscessus subsp. bolletii* and *M. abscessus subsp. massiliense* and has been associated with various clinical manifestations, including cutaneous, soft tissues, disseminated infections or lung infections. The pulmonary infections are particularly problematic to treat in the context of cystic fibrosis patients that are highly vulnerable to *M. abscessus complex*. *M. abscessus* is also recognized as one of the most antibiotic-resistant mycobacterial species, leaving clinicians with few therapeutic options. Standard drug regimens against *M. abscessus* lung diseases usually combine three antibiotic classes: an aminoglycoside (amikacin), a macrolide...
(clarithromycin) and a β-lactam (cefoxitin or imipenem). However, *M. abscessus* is often refractory to these chemotherapies. The extreme resistance levels of this bacteria to most conventional antibiotics is notably well exemplified by the fact that *M. abscessus* is resistant to all first-line anti-tubercular drugs (isoniazid, rifampicin, pyrazinamide).

In addition to drug target modification, resistance mechanisms in *M. abscessus* involve also intrinsic drug resistance, low permeability of the cell wall, induction of drug efflux pumps, absence or non-functional drug-activating enzymes which no longer convert pro-drugs into active metabolites.

Amikacin (AMK), a widely used antibiotic for the treatment of *M. abscessus* lung infection, is inactivated by the N-acetyltransferase Eis2\textsubscript{Mab}\cite{17,18}. Biochemical and structural studies indicated that Eis2\textsubscript{Mab} accommodates a wide range of aminoglycosides in its active site where they are modified by the addition of one or several acetyl groups on their primary amine function, thus impeding their interaction with the ribosome\cite{18,8}. Solving the high-resolution structure of Eis2\textsubscript{Mab} proved that this protein accommodates amikacin in its active site where the drug undergoes acetylation as supported in enzymatic assays\cite{18}. Importantly, the deletion of eis2\textsubscript{Mab} increases the susceptibility of *M. abscessus* to aminoglycosides, thus supporting our findings\cite{17}. Noteworthy, a recent study demonstrated the Eis2\textsubscript{Mab}-dependent enhanced intracellular survival of *M. abscessus* in human macrophages, suggesting that Eis2\textsubscript{Mab} and Eis\textsubscript{Mtb} share a similar biological function\cite{19}. In contrast to *M. tuberculosis*, the *M. abscessus* genome encodes a second Eis protein homologous to Eis2\textsubscript{Mab}, designated Eis1\textsubscript{Mab} and encoded by *MAB_4124*. However, inactivation of eis1\textsubscript{Mab} only modestly impacted the capacity of the mutant strain to infect macrophages and failed to modify the susceptibility to aminoglycosides as compared to an eis2\textsubscript{Mab} mutant\cite{19}. This suggests that Eis1\textsubscript{Mab} and Eis2\textsubscript{Mab} share very limited overlapping functions\cite{17,19}. The reasons for these differential biological functions between Eis1\textsubscript{Mab} and Eis2\textsubscript{Mab} remain obscure when considering the primary sequence identity (31\%) between the two proteins. To fill this gap, and in order to provide the mechanistic basis explaining these differential aminoglycoside-modifying properties, a thorough structural and biochemical study of Eis1\textsubscript{Mab} was undertaken.

**Materials and Methods**

1- Inactivation of eis1 in *M. abscessus*.

Deletion of *MAB_4124* (eis1\textsubscript{Mab}) and *MAB_4532c* (eis2\textsubscript{Mab}) in the reference strain *M. abscessus* CIP104536 was carried out using the double homologous recombination unmarked
The DNA sequences located upstream and downstream the eis1 \textsubscript{Mab} gene were PCR-amplified and subsequently cloned into the pUX1-katG using the following primers and containing specific restriction sites (capital letters): fw\_up\_eis1\_NheI 5'-gatcCGCTAGcgcacccgtcagatacagggttctc-3'; rv\_up\_eis1\_MfeI 5'-ggateCAATTGcgtcagctttgctggtttggttc-3'; fw\_down\_eis1\_MfeI 5'-gatccCAATTGacttctaggagtctgccgtgtccatccaggaac-3'; rv\_down\_eis1\_HpaI 5'-ggateGTAAACcaaggctagtgcgcgagcagcggcg-3'.

The DNA sequences located upstream and downstream the eis2 gene were PCR-amplified and subsequently cloned into the pUX1-katG plasmid using the following primers and containing specific restriction sites (capital letters): fw\_up\_eis2\_HpaI: 5'--catccGTAAACctggagctgctccgatgagccgaaatatgc-3'; rv\_up\_eis2\_MfeI: 5'-gatccCAATTGgtgcgtagggtcagctcagacacatacccatg-3'; fw\_down\_eis2\_NheI: 5'-gatccGCTAGCgggatcgatcagcattactgtgtacagtcc-3'; rv\_down\_eis2\_MfeI: 5'-gatccCAATTGgtttggctggcccgtcgcacccagtgcgcc-3'.

The resulting plasmids were introduced by electroporation in the smooth (S) variant of \textit{M. abscessus} and the red fluorescent, kanamycin (KAN)-resistant colonies which underwent the first homologous recombination event were selected on Middlebrook 7H10 agar supplemented with 10% Oleic acid-Albumin-Dextrose-Catalase (OADC) in the presence of 200 \(\mu\)g.mL\(^{-1}\) KAN. Cultures of selected colonies were then subjected to a counter-selection on 7H10 agar plates supplemented with OADC containing 50 \(\mu\)g.mL\(^{-1}\) isoniazid (INH) to promote a second homologous recombination and removal of the KAN cassette. Non-fluorescent, INH-resistant colonies were picked up and further genotyped for eis1\textsubscript{Mab} deletion following PCR using two pairs of primers: fw\_up\_eis1\_NheI with SQ2\_b\_down: 5'-cttactagaggagccatgggttctc-3' and SQ2\_a\_down: 5'-cgccaactctgggttggatctc-3' with SQ2\_b\_down. Identification of eis2 mutants was performed by PCR using this pair of primers: SQ1\_a\_up: 5'-gcctggagtacagcgcaggtaccgg-3' and SQ1\_b\_up: 5'-ggcctggagtacagcgcaggtaccgg-3'. The positive clones were further confirmed by DNA sequencing of the genomic region surrounding the site of gene deletion.

For functional complementation of the eis1\textsubscript{Mab} deletion mutant (\(\Delta\)eis1\textsubscript{Mab}), the genomic sequence of eis1\textsubscript{Mab} was fused at its 5' end in frame with the sequence encoding the Streptag-II (italic letters), using the following primers (restriction sites in capital letters): \textit{fw}_Eis1\_261\_NdeI 5'-ctcaacATATGatgTGGAGCCACCGCGCATTCGAGAAGatggccttcaggcggcgagcctcaatggc-3' and \textit{rv}_Eis1\_261\_HindIII 5'-caatgAAGCTTcagaagttgcgcagcgcagctc-3' and subsequently cloned into pMV261-Zeo \(^{21}\) in which the kanamycin cassette has been replaced by a zeocine resistance cassette, between NdeI and HindIII. We used similar strategy to complement the \(\Delta\)eis2\textsubscript{Mab} mutant by cloning the eis2 gene into pMV261-Zeo using the following primers (restriction sites in capital
letters): \[ \text{fw}_{\text{Eis2}}_{\text{261}}_{\text{NdeI}} \]

tctcaACTATGatgTGGAGCCACCCGCAGTCTGAGAAGatgtctgagctgaccctacgcaccattg

-3' and \( \text{rv}_{\text{Eis2}}_{\text{261}}_{\text{HindIII}} \) 5'

caatgAAGCTTtcagaagtcgtcgggcgcactgggtgc

-3'.

The parental, \( \Delta \text{eis}1 \) and \( \Delta \text{eis}2 \) \( M. \text{abscessus} \) strains were transformed with either pMV261-Zeo, pMV261-Zeo-eis1 or pMV261-Zeo-eis2 and selected onto 7H10 agar supplemented with OADC and 50 \( \mu \text{g.mL}^{-1} \) Zeocin.

2-Amikacin susceptibility assessment.

The different strains were grown in Sauton’s broth medium supplemented with 10\%(v/v) OADC/ 0.025\%(v/v) tyloxapol and 50 \( \mu \text{g.mL}^{-1} \) zeocin. The exponential bacterial cultures were pelleted and resuspended in PBS buffer. Five microliters of 10-fold serially diluted \( M. \text{abscessus} \) cultures were spotted on LB plates in the absence or presence of 4, 8 and 12 \( \mu \text{g.mL}^{-1} \) AMK. Plates were incubated at 37°C for 3 days.

3-Cloning, protein expression, and purification

The codon-optimized sequence (GenScript) encoding \( \text{eis}1_{\text{Mab}} \) was cloned into pET-41 between the KpnI and EcoRI restriction sites in frame with the N-terminal Glutathione S-transferase (GST) tag followed by a Tobacco Etch Virus (TEV) protease cleavage site. An overnight culture of \( \text{Escherichia coli} \) BL21 (DE3) strain resistant to Phage T1 (New England Biolabs, Evry, France) carrying pRARE2 and transformed with pET41-\( \text{eis}1_{\text{Mab}} \) was grown under agitation at 180 rpm at 37 °C in LB medium supplemented with 50 \( \mu \text{g.mL}^{-1} \) KAN and 30 \( \mu \text{g.mL}^{-1} \) chloramphenicol. This preculture was used to inoculate 6 L of LB broth supplemented with the same antibiotics at 37 °C. The cultures were cooled down in ice for 30 min when OD\text{600} reached \~0.8 and protein expression was induced with 1 mM of Isopropyl-\( \beta \)-D-thiogalactoside (IPTG) (Euromedex) for 16 h at 18 °C. Cell pellets were collected by centrifugation at 6, 000 g for 20 min and resuspended in buffer A (50 mM Tris-HCl pH 8, 0.4 M NaCl, 1 mM \( \beta \)-mercaptoethanol, and 1 mM benzamidine). Bacteria were lysed by sonication and cell lysates were clarified by centrifugation at 28, 000 g at 4°C for 1 h. The supernatant was then incubated 30 min with GST-sepharose beads with gentle agitation before being loaded onto a gravity column. Beads were washed with 10 column volumes of buffer B (50 mM Tris-HCl pH 8, 0.4 M NaCl, 1 mM \( \beta \)-mercaptoethanol) and buffer C (50 mM Tris-HCl pH 8, 1 M NaCl, 1 mM \( \beta \)-mercaptoethanol). Proteins were finally eluted with buffer D (50 mM Tris-HCl pH 8, 0.2 M NaCl, 1 mM \( \beta \)-mercaptoethanol and 15 mM glutathione). The eluate was incubated with TEV protease (1 mg of TEV protease per 40 mg of protein) and dialyzed overnight against
buffer E (20 mM Tris-HCl pH 8, 0.2 M NaCl, 1 mM β-mercaptoethanol). A Nickel-Nitrilotriacetic acid sepharose column was used to adsorb the His-tagged TEV protease, the cleaved tag and the uncleaved tagged protein. The tag-free protein that weakly binds to the column was collected by washing the column with buffer E supplemented with 50 mM imidazole. The protein was concentrated using a 10 kDa cut-off centricon (Sartorius) and purified by size-exclusion chromatography on a Superdex 200 Increase 10/300 GL column (GE Healthcare) with buffer F (20 mM Tris-HCl pH 8, 0.2 M NaCl). The protein concentration was determined using a Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific) and the protein purity was estimated by Coomassie blue staining. Eis2\text{Mab} was expressed and purified, as described previously.\cite{18}

4-Enzyme kinetic assays

Eis1\text{Mab} and Eis2\text{Mab} were freshly purified in buffer F. The CoA-SH product of the acetyltransferase reaction triggers the reduction of DTNB (5,5-dithio-bis(nitrobenzoic acid) to form TNB (2-thio-5-nitrobenzoic acid, extinction coefficient: 14150 M$^{-1}$cm$^{-1}$) with a peak of absorption at 412 nm. A master stock of KAN (containing 96% Kanamycin A and 4% KAN B), APR (Apramycin), ZEO (Zeocin), AMK (Amikacin), HYG (Hygromycin B), TYR (Tyramine), HIS (Histamine), acetyl-CoA (ACO) and enzymes were dissolved and diluted in buffer F. The premix A (enzyme, ACO, DTNB) and premix B (DTNB, substrate) were first incubated for 5 min at 25 °C. The reaction was initiated and measured immediately after combining both premixes to a final volume of 100 µL containing 0.25 µM enzyme, 0.5 mM ACO, 2 mM DTNB, and 5 mM of each substrate for assessment of the enzyme specificity. For kinetic constants determination one of the concentration either 5 mM TYR or 0.5 mM ACO was kept constant and the concentration of the other one varied. The reaction was followed at 25 °C and data points were recorded every 5 s for 90 s in a quartz cuvette and using a Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific). All absorbance values were normalized against a negative control where the substrate was absent and standard errors were calculated from three replicates. Nonlinear least-squares regression was used to determine the Michaelis-Menten equation (Prism software, GraphPad).

5-Assessment of protein expression by Western-Blot

Single colonies were inoculated in 100 mL of Sauton’s broth supplemented with 10%(v/v) OADC/0.025%(v/v) tyloxapol and 50 µg.mL$^{-1}$ zeocin and grown for 3 days at 37 °C, under agitation at 120 rpm. Bacteria were harvested by centrifugation and resuspended in buffer A, described above. After opening bacteria by bead-beating and sonication, samples were centrifuged at 20, 000
g, at 4 °C. The supernatant was collected, mixed with loading-blue buffer and separated on SDS-PAGE. Proteins were then transferred onto a nitrocellulose membrane (GE Healthcare) in transfer buffer (20 mM Tris, 150 mM Glycine, 20% (v/v) ethanol). The membrane was saturated by blocking buffer (PBS 1X, 5% (m/v) skimmed milk, 0.2% (v/v) Tween 20) followed by incubation with primary monoclonal Anti-Strep-tag antibodies produced in mouse (dilution 1/10000) (Sigma-Aldrich). Bands were revealed by polyclonal anti-mouse antibodies conjugated to the horseradish peroxidase (dilution 1/5000) (Sigma-Aldrich). Protein were detected by the luminol-based reaction (SuperSignal™–Thermo Fisher Scientific) and imaged by a Chemidoc (Biorad).

6-Crystallization and x-ray data collection

Crystals were grown in sitting drops in MR Crystallization Plates™ (Hampton Research) at 18 °C by mixing 2 µL of protein solution concentrated to 0.4 mg.mL⁻¹ and containing 2 mM ACO with 2 µL of reservoir solution consisting of 0.8 M ammonium sulfate, 0.1 M Bis-Tris pH 5.5 and 1% (w/v) PEG 3350. Crystals were grown for one month and cryoprotected by a brief soaking step into a solution made of 1.4 M ammonium sulfate, 0.1 M Bis-Tris pH 5.5, 1% (w/v) PEG 3350 and 10% glycerol (v/v) prior being cryo-cooled in liquid nitrogen. X-ray diffraction data were collected at the Swiss-light source on the X06DA-PXIII beamline.

7-Structure solving and refinement

The Eis1Mab structure was solved by molecular replacement using the crystal structure of the Eis2Mab monomer bound to ACO (PDB: 6RFT) as a search request and sharing 31 % primary sequence identity with Eis1Mab. Molrep from the CCP4i package was used to performed molecular replacement. Six molecules were found in the asymmetric unit. After a first refinement step leading to R/Rfree of 0.46/0.5, Autobuild from the Phenix software suite was further used to automatically improved the model building which led to R/Rfree: 0.32/0.41. The model was further manually rebuilt and refined using Coot and the Phenix software suite. This led to a final model with refinement statistics shown in Table 1. The coordinates and structures factors have been deposited at the protein data bank under accession number: 6YCA.

Results

1-Overexpression of Eis1Mab does not induce aminoglycoside resistance in M. abscessus
A previous study reported that the deletion of eis₁<sub>Mab</sub>, but not eis₂<sub>Mab</sub>, was associated with an unchanged susceptibility profile to aminoglycosides, leading the authors to conclude that only eis₂<sub>Mab</sub> participates in resistance to this class of antibiotics<sup>17</sup>. However, as emphasized by these authors, additional studies are required to confirm or dismiss the implication of Eis₁<sub>Mab</sub> in aminoglycoside resistance, particularly by determining the antibiotic susceptibility pattern of a strain overexpressing Eis₁<sub>Mab</sub>. To address these two possibilities, eis₁<sub>Mab</sub> was cloned into the episomal pMV261-Zeo construct under the control of the strong hsp60 promoter, yielding pMV261-Zeo-eis₁<sub></sub>, to achieve high levels of protein expression. To easily monitor the expression of Eis₁<sub>Mab</sub> by Western blotting, the protein was expressed as a fusion protein harboring a Streptag-II in its N-terminus. Moreover, a Δeis₁<sub>Mab</sub> deletion mutant was generated in the smooth variant of M. abscessus using a recently established recombineering procedure that allows the generation of unmarked gene deletion (Figure 1A and Figure 1B)<sup>20</sup>. Both the parental and Δeis₁<sub>Mab</sub> strains were transformed with either the empty pMV261-Zeo or pMV261-Zeo-eis₁<sub></sub>. Zeocin was chosen as a selection marker as it does not belong to the aminoglycoside class of antibiotics and thus, the ZEO resistance cassette is very unlikely to affect the aminoglycoside susceptibility profile of the different strains tested. To include a control strain with increased susceptibility to aminoglycosides, we also generated a Δeis₂<sub>Mab</sub> deletion mutant known to be susceptible to AMK<sup>17</sup> and complemented strain (Figure S1).

Probing bacterial lysates of three independent clones using anti-Strep tag antibodies testified that high expression levels of Eis₁<sub>Mab</sub> and Eis₂<sub>Mab</sub> were achieved in both the wild-type, Δeis₁<sub>Mab</sub> and Δeis₂<sub>Mab</sub> strains carrying pMV261-Zeo-eis₁<sub></sub> or pMV261-Zeo-eis₂<sub></sub> (Figure 1C and Figure S1). Next, we tested whether overexpression of Eis₁<sub>Mab</sub> in both wild-type and Δeis₁<sub>Mab</sub> strains was associated with increased resistance to aminoglycosides on agar plates supplemented with increasing concentrations of APR, HYG or AMK. No major growth defect was noticed between the different strains plated on either drug as shown for AMK (Figure 1D). Conversely, the Δeis₂<sub>Mab</sub> mutant was hypersensitive to AMK as compare to all the other strains (Figure 1D). Overexpression of Eis₂<sub>Mab</sub> in the mutant rescued this effect and growth occurred even in the presence of 12 µg.mL<sup>-1</sup> of AMK, the highest concentration tested (Figure 1D). These results corroborate previous findings suggesting that unlike Eis₂<sub>Mab</sub>, Eis₁<sub>Mab</sub> is not a primary determinant of resistance to aminoglycosides<sup>17</sup>.

2-Eis₁<sub>Mab</sub> is an active N-acetyltransferase but does not modify aminoglycosides
We next investigated the biochemical properties of Eis1\textsubscript{Mab}. It was previously reported that recombinant Eis1\textsubscript{Mab} tends to aggregate, rendering the purification procedure challenging\textsuperscript{8}. Likewise, we were facing the same issues when Eis1\textsubscript{Mab} was fused to small tags at its N-terminus, such as His- and S-tags. This tendency to aggregate may suggest a folding issue of the protein and, may explain, at least partly, the lack of activity of Eis1\textsubscript{Mab}\textsuperscript{8}. To circumvent this problem, we attempted to increase protein solubility by overexpressing Eis1\textsubscript{Mab} fused to the Glutathione-S-transferase (GST) in its N-terminus. This greatly increased the solubility of the protein and to purify it via a three-step purification procedure. Eis1\textsubscript{Mab} did not aggregate after removal of the GST-tag and, as long it was not too concentrated, a homogeneous and sharp peak could be observed on gel-filtration (Figure 2). The size-exclusion elution profile strongly suggests that Eis1\textsubscript{Mab} behaves as a multimer in solution. A calibration curve allowed to calculate an apparent molecular weight of 198 kDa, similar to the one reported for its closest homologue Eis2\textsubscript{Mab}\textsuperscript{18} or to those of Eis from \textit{M. tuberculosis} or \textit{M. smegmatis}\textsuperscript{25}. From this, it can be inferred that Eis1\textsubscript{Mab} is a hexamer in solution.

The substrate specificity of Eis1\textsubscript{Mab} was next assessed \textit{in vitro} by enzymatic assay but no activity was detected towards a range of aminoglycoside antibiotics. However, an N-acetyltransferase activity was detected when using arylalkylamine substrates, such as TYR and HIS (Figure 3A and 3B). These two substrates are smaller compare with aminoglycosides (Figure 3A) and possess primary amine groups. TYR and HIS are known to be acetylated by different N-acetyltransferases and are substrates of Eis from \textit{M. tuberculosis} and \textit{M. smegmatis}\textsuperscript{26}. Interestingly, Eis1\textsubscript{Mab} was found to be more active towards TYR and HIS than Eis2\textsubscript{Mab} (Figure 3B).

This prompted us to determine the kinetic constants of Eis1\textsubscript{Mab} for TYR, which appears as the preferred substrate of the enzyme (Figure 3B). As could be expected for noncognate substrates the $K_M = 722 \pm 21$ µM and $k_{cat} = 11 \pm 0.5$ s\textsuperscript{-1} for TYR are suggestive of moderate activity. Eis1\textsubscript{Mab} displays also a slightly lower affinity ($K_M = 144 \pm 19$ µM) for ACO as compared to Eis2\textsubscript{Mab} ($K_M = 36.2 \pm 2.9$ µM)\textsuperscript{18} and to Eis homologous proteins\textsuperscript{8} which all display $K_M$ values < 50 µM (Figure 3C). Nonetheless, these \textit{in vitro} data support the view that Eis1\textsubscript{Mab} purified under our experimental procedure is an active N-acetyltransferase and, in contrast to Eis2\textsubscript{Mab}, does not modify aminoglycosides. The smaller substrate preference of Eis1\textsubscript{Mab} as compared to Eis2\textsubscript{Mab} makes it a noticeable feature that distinguishes the two enzymes.

3-Overall crystal structure of Eis1\textsubscript{Mab}

To get insights into the molecular basis driving the Eis1\textsubscript{Mab} substrate specificity, we aimed at resolving the crystal structure of the protein. Extensive screening for crystallization conditions
using either the apo- or ACO-bound form of Eis1_Mab generated numerous crystals. However, only crystals of the (ACO)-bound form of Eis1_Mab allowed the collection of exploitable datasets. We solved the crystal structure by molecular replacement using Eis2_Mab as a search model and the model was refined to a resolution of 2.9 Å (Table 1). Most residues could be modeled except for the first 23 N-terminus amino acids and part of helix 2 in all monomers.

The overall structure of Eis1_Mab is a multimer formed by six monomers. This hexameric architecture is similar to the organization of proteins belonging to the GNAT superfamily and also to Eis2_Mab and to its homologues in M. tuberculosis (Eis_Mtb) and M. smegmatis (Eis_Msm). It consists of the superposition of two homotrimers with a central vestibule (Figure 4A). This oligomeric state fully agrees with the apparent molecular mass determined by size-exclusion chromatography (Figure 2). The structure of the Eis1_Mab monomer can be divided into three subdomains: the N-terminal GNAT domain (residues 1-135), the central GNAT domain (residues 136-312) and the C-terminal domain (residues 313-415). Each monomer is composed of seventeen β-strands (β1 to β17), ten α-helices (α1 to α10) and seven 3₁₀ helices (η1 to η7) (Figure 4B).

4-The Acetyl-CoA binding site of Eis1_Mab

The best diffracting Eis1_Mab crystals were obtained in the presence of ACO. The simulated-annealed OMIT electron density map certifies the presence of the cofactor in the Eis1_Mab structure (Figure 4C). Due to the medium resolution, no water molecule could be modeled but fourteen residues involved in cofactor recognition could be identified (Figure 4D). While the side chains of Leu135 and Ile142 are involved in hydrophobic interactions, the His101 main chain provides a weak H-bond with the oxygen of the acetyl moiety. The carbonyl of Ile102 and Val104 establish also H-bonds. The ACO phosphate groups are recognized by the main chains of Arg110, Gly112, Ile114, and Thr115, as well as by the side chain of Thr115. Arg110 plays a key role in the interaction by making a salt-bridge with the phosphate group, creating a H-bond with the O group and a stacking interaction with the adenine ring of ACO. The carboxyl group of Glu139 binds to the NH2 of the adenine ring whereas Ser138 interacts with the O group of ACO. The Arg145 guanidium group recognizes the O4 of the ribose of ACO (Figure 4D). Additionally, multiple primary sequence alignments indicate that the cofactor binding site is relatively well conserved among the mycobacterial Eis proteins (Figure 5). Therefore, we rule out the possibility that these few amino acid substitutions in the cofactor binding site of Eis1_Mab would explain the difference of the substrate specificity between Eis1_Mab and the other Eis proteins.
5- The structural basis for Eis1Mab substrate specificity

We next searched at the Protein Data Bank using the eFOLD (https://www.ebi.ac.uk/msd-srv/ssm/) and DALI servers for the closest homologues of Eis1Mab. First of all, we superposed Eis homologues structures from proteins that have been biochemically characterized and have been reported to modify aminoglycosides. The multiple sequence alignments (Figure 5) and superposition of the Eis1Mab monomer to the other Eis:ACO or Eis:CoA bound structures (Figure 6A) generated the following primary sequence identity and root mean square deviation (r.m.s.d.) values: EisMtb (PDB id: 3RYO, 30% identity, r.m.s.d. 1.8 Å) 

EisMsm (PDB id: 3SXN, 31% identity and r.s.m.d. 1.8 Å) 

Eis2Mab (PDB id: 6RFT, 31% seq identity, r.m.s.d. 2.1 Å) 

Anabaena variabilis, EisAva, (PDB id: 2OZG, 20% and r.m.s.d. 2.2 Å), unpublished. Additionally, the structure of EisBan from Bacillus anthracis (PDB id: 3N7Z) solved without cofactor displays low sequence identity, 17% but a similar r.s.m.d of 2.1 Å. Our search allowed the comparison of two other Eis homologues that were not biochemically characterized, for instance, the EisEfa from Enterococcus faecalis, with no ligand (PDB id: 2I00, 17%, r.m.s.d. 2.10 Å), and EisKfl from Kribbella flavida (PDB id: 4MY0, 21%, r.m.s.d. 2.4 Å). This structural comparison indicate that the closest homologues of Eis1Mab are Eis proteins from the mycobacterium phylum.

To understand the structural features responsible for Eis1Mab’s preferences for small substrates, the crystal structure of Eis1Mab was compared with those of EisMtb and EisMsm which were solved in the presence of aminoglycosides. EisMtb was co-crystallized with tobramycin (PDB id: 4JD6) and EisMsm with paromomycin (PDB id: 4QB9). Most residues seen interacting with tobramycin in Eis1Mab are not conserved except for the ultra-conserved carboxy-terminal Phe residue (Figure 5). Furthermore, among the eleven residues contacting paromomycin in EisMsm, only three residues are semi-conserved (Thr100, His101, and Glu307) in Eis1Mab while two others are strictly conserved (Ser138 and Phe415 at the C-terminus) (Figure 5). However, due to the partial conservation in the overall primary sequence between EisMtb, EisMsm, and Eis2Mab (Figure 5), it remains difficult to state that the inability of Eis1Mab to modify aminoglycosides is inherent to the absence of amino acids conservation in the substrate-binding pocket. We, therefore, hypothesized that the size of Eis1Mab active site pocket may be reduced as compared with other Eis proteins. Determination of the central cavity volume that includes both the cofactor and substrate binding sites of each Eis protein was carried out with the CASTp server and, using its default settings. This analysis showed that Eis1Mab has a rather small cavity of 651 Å³ in comparison with the other Eis members that were experimentally shown to acetylate aminoglycosides (2005 Å³ for EisMtb, 1678 Å³ for EisMsm, 1371 Å³ for EisAva and 1274 Å³ for Eis2Mab). Only EisBan has a slightly bigger volume than Eis1Mab (695 Å³) (Figure 6B). Comparison of Eis1Mab with EisMtb, which possesses the
largest cavity allows proposing that the small cavity in Eis1Mab results of the positioning of helix 4 which pushes further away helix 5. Consequently, this places the bulky side chains of residues Trp205, His210, and Phe213 closer to the Phe415 at the C-terminus, known to be required for substrate recognition (Figure 6C). These structural features reducing the volume of the Eis1Mab substrate cavity are not seen in EisMtba, as the less bulky side chains of the equivalent residues Leu196, Leu200 and Glu202 are not protruding into the aminoglycoside-binding cavity (Figure 6C).

The structural comparison of the various Eis proteins unraveled an atypical feature in the central GNAT domain of Eis1Mab (Figure 5 and Figure 6A). The region composed of fourteen residues and ranging from residues 235 to 248 (235-PQDTAEWFSSSART-248) is forming a loop and a 3_10 helix (η4, Figure 4B). This region spanning between strands β9 and β10 is extended in Eis1Mab as compared with the other Eis proteins. This loop seems to act as a lid covering the substrate-binding site of the neighbor subunit (Figure 7A). Hence, this region might restrict the accessibility of the substrate-binding pocket to bulky molecules. Furthermore, Phe242, which is not conserved in other Eis homologues (Figure 5) seems of particular interest since its bulky side chain is protruding into the substrate-binding pocket, as can be appreciated when Eis1Mab is superposed onto the tobramycin-bound EisMtba structure (Figure 7A). This may further reduce the volume of the substrate-binding site, thus compromising the access to large substrates, like aminoglycosides. Of note, this loop between strands β9 and β10 as well as Phe242 is strictly conserved in all subspecies of the M. abscessus complex (data not shown). Moreover, the corresponding loop was found to be much shorter in all the Eis proteins for which the enzymatic activity towards aminoglycosides was experimentally demonstrated. The loop of EisMtba or EisMsm possesses 8 residues (228-VDRTDLKL-235) and 7 residues (226-RGPDGRR-232), respectively (Figure 7B). Additionally, even shorter loops are seen in two other Eis proteins whose activity towards aminoglycosides was demonstrated 29,28 the loops in the EisBan (219-ENYK-222) and EisAva (221-RTRDGS-226) crystal structures are made of 4 and 6 residues, respectively (Figure 7B).

Discussion

Mycobacterial N-acetyltransferases and particularly Eis proteins play important roles in macrophage invasion, persistence, modulation of the immune response and antibiotic resistance 33. Eis proteins modify a large set of aminoglycosides and have an impact on antibiotic resistance in numerous mycobacterial species, notably in M. tuberculosis and in NTM, including M. abscessus 18,17 and M. fortuitum 33. Thus, molecules inhibiting Eis proteins given in combination with aminoglycosides would broaden the efficacy of this class of antibiotics in the fight against mycobacterial infections 34. The other biological functions of Eis protein related to the enhanced
intracellular survival or to the modulation of the immune response of the host are also of interest in terms of druggability. Despite being closely related, the contribution of Eis1\textsubscript{Mab} and Eis2\textsubscript{Mab} to the intracellular survival of \textit{M. abscessus} differs. While the deletion of \textit{eis1\textsubscript{Mab}} only slightly impairs the survival of \textit{M. abscessus} in macrophages, the deletion of \textit{eis2\textsubscript{Mab}} profoundly affects the intracellular survival of the mutant strain \textsuperscript{19}. Additionally, regulation of the intracellular expression of the two genes is opposite as \textit{eis1\textsubscript{Mab}} is downregulated while \textit{eis2\textsubscript{Mab}} is upregulated in \textit{M. abscessus}-infected macrophages \textsuperscript{19}. Importantly, our study unambiguously establishes that in contrast to Eis2\textsubscript{Mab}, Eis1\textsubscript{Mab} is not implicated in resistance to aminoglycosides, supporting previous findings \textsuperscript{8,17,35}. This absence of redundant function between the two Eis homologues makes Eis2\textsubscript{Mab} as an interesting drug target to explore further to tackle drug resistance and virulence of \textit{M. abscessus}.

Solving the crystal structure of Eis1\textsubscript{Mab} sheds new light into the differential biological functions of Eis proteins in general and Eis1\textsubscript{Mab} and Eis2\textsubscript{Mab} more particularly. Structural comparison of many Eis structures belonging to the Mycobacterium or to other phyla identified key structural elements that are likely to block the access of Eis1\textsubscript{Mab} binding site to large substrates such as aminoglycosides. In particular, the existence of an extended loop acting as a lid and covering the active site of the neighbor monomer as well as the positioning of helices 4 and 5 restrict the accessibility to the active site. Future work should be dedicated to investigating in more detail the substrate specificity of Eis1\textsubscript{Mab} by creating defined mutants in the extended loop and/or $\alpha4$-$\alpha5$ helices. This appears achievable as modulation of the Eis\textsubscript{Mtb}'s substrate specificity was successfully done by mutating bulky residues that restrict the entrance of the active site \textsuperscript{36}.

This work may also add meaningful information allowing to predict the Eis-like protein substrate specificity. Like \textit{M. abscessus}, other mycobacterial species possess several paralogues of the Eis protein \textsuperscript{33}, and predicting the function of these proteins particularly in the case of pathogenic bacteria may help to anticipate whether these Eis-like proteins may play a role in resistance to aminoglycosides. In that regard, bioinformatics tools such as multiple primary sequence alignments combine with protein structure homology modeling, could be useful to estimate the size of the loop between strands 9 and 10 (or strands 10 and 11 depending of the Eis origin) of the Eis homologues and consequently their substrate specificity.

While Eis1\textsubscript{Mab} cannot modify aminoglycosides, our results indicate that it is an active N-acetyltransferase towards the small TYR and HIS arylalkylamine compounds, which are very unlikely the “natural substrates” of the enzyme. In the quest of identifying possible substrate of Eis1\textsubscript{Mab} we carefully analyzed the genomic environment around \textit{eis1\textsubscript{Mab}}, and found that it probably belongs to an operon that is extremely well conserved among all the three \textit{M. abscessus} subspecies and in other NTM, such as \textit{Mycobacterium chelonae}, \textit{Mycobacterium saopaulense} or
Mycobacterium immunogenum. This operon also encompasses genes coding for a putative permease (MAB_4122), a predicted monooxygenase/acyl-CoA dehydrogenase (MAB_4123) located upstream of eis1Mab and a nitrilotriacetate monooxygenase (MAB_4125) possessing a bacterial luciferase predicted domain, downstream of eis1Mab. MAB_4122 and MAB_4125 are close homologues of the dibenzo thiophene desulfurization enzymes A and C present in numerous bacteria able to degrade dibenzo thiophene, an organosulfur compound found in petroleum 37. Interestingly, the existence of such degradation pathway has also been described in Mycobacterium phlei 38, which also possesses one Eis-like protein. Although Eis-like N-acetyltransferases have not been found yet functionally linked to such degradation pathway, this conserved genomic organization suggests that Eis1Mab might be a new partner of this organosulfur chemicals degradation/detoxification pathway. This may be relevant to the fact that NTMs are environmental bacteria, which are likely to encounter organosulfur compounds in their ecological niche. In addition, that dibenzo thiophene derivatives are also potent inhibitors of M. tuberculosis 39 may suggest that the eis1Mab operon participates in resistance of M. abscessus to these compounds.

Conflict of interest statement
The authors declare no conflict of interest.

Acknowledgements
We thank the staff at SLS beamlines for support during data collection, the Fondation pour la Recherche Médicale (FRM) [grant number DEQ20150331719 to LK], and A. Viljoen for fruitful discussion. KLU Ph.D. fellowship is supported by the National Research Agency [ANR-17-CE11-0008-01 – MyTraM to MB]

Author contributions
KLU and MB designed and performed experiments. MB and LK supervised research. MB wrote the first draft with input of all the authors.

References


Figure legends

Figure 1: Aminoglycosides susceptibility assessment of Eis1-overexpressing M. abscessus strains.
A Schematic representation of the genomic region around eis1 in the parental (WT) and Δeis1 mutant strains of M. abscessus. Sizes of the PCR amplicons used for genotyping of the Δeis1 mutant are shown. B PCR profile confirming the proper deletion of eis1 in the mutant strain. Two PCR products of 1.8 and 2.9 kb were amplified from Δeis1 genomic DNA while two bands at 4 and 2.9 kb are expected for the WT strain. C Protein expression pattern of Eis1Mab in parental (WT) and knockout strains. Western blotting using anti-Strep-tag primary antibodies attest for the expression of Eis1Mab in the two strains transformed with pMV261-Zeo-eis1 in three individual colonies (C1-C3). Strain transformed with the empty pMV261-Zeo were included as negative controls. The band at 70kDa of the protein ladder possesses also a Strep-tag explaining its immune reactivity with the antibody. D Amikacin susceptibility profile of parental (WT), Δeis1 M. abscessus strains overexpressing Eis1Mab and Δeis2 M. abscessus strains overexpressing Eis2Mab. Serial dilutions of bacteria carrying either pMV261-Zeo, pMV261-Zeo-eis1 or pMV261-Zeo-eis2 were spotted onto LB agar supplemented with increasing concentrations of AMK and incubated at 37 °C for 3 days. The figure is representative of two independent experiments.

Figure 2: Determination of the oligomeric state of Eis1Mab

Estimation of the oligomeric state of recombinant Eis1Mab by size-exclusion chromatography (left panel). The elution profile of the proteins used for calibration is displayed as a black line and the elution profile of Eis1Mab is shown in red. The calibration curve was established using β-amylase (1) (200 kDa), bovine serum albumin (2) (66 kDa), carbonic anhydrase (3) (29 kDa) and cytochrome C (4) (12.4 kDa), eluted with estimated volumes of 11.02, 13.2, 15.8 and 17.4 mL, respectively. The void volume corresponds to the dextran blue elution peak at 8.5 mL. The elution peak of Eis1Mab at 10.9 mL matches an apparent molecular weight of 198 kDa. Coomassie Blue-stained SDS polyacrylamide gel electrophoresis of Eis1Mab produced after the last step of purification on size-exclusion chromatography (10 μg of protein; right panel).

Figure 3: Biochemical characterization and enzymatic activity of Eis1Mab

A Chemical structures of the different substrates tested in the assay. The structure of zeocin which is a very large molecule is not displayed. B Initial rates of Eis1Mab determined in the presence of various substrates, including apramycin, hygromycin, kanamycin, zeocin, tyramine and histamine at a concentration of 5 mM. As a positive control, purified Eis2Mab was also tested with TYR and HIS. C Michaelis and Menten curves used to determine the kinetic constants for TYR (left panel) and ACO (right panel).
Figure 4: Overall three-dimensional structure of Eis$_{1\text{Mab}}$.

A Overall crystal structure of Eis$_{1\text{Mab}}$ bound to ACO. The structure of the Eis$_{1\text{Mab}}$ hexamer is depicted as a cartoon representation where each chain is colored differently. The left panel is a top view of the structure and the right one is rotated by 90°. ACO is pictured in each chain as a sphere representation. B Cross-eye stereo view of the Eis$_{1\text{Mab}}$ monomer. The three domains are displayed as a cartoon representation where the N-terminal (Nt) GNAT domain is displayed as raspberry color, the central GNAT domain is in blue and the C-terminal (Ct) GNAT domain is in yellow. α, β and η indicate α-helices, β-strands, and 3$_{10}$ helices respectively. C Fo-Fc simulated-annealed OMIT map. The electron density map surrounding the ACO ligand is displayed as a grey mesh and contoured at 2.8 σ level. D ACO interactions with the Eis1 residues are shown as white sticks. Hydrogen-bond and the salt-bridge interactions are shown as black dashed lines.

Figure 5: Structural comparison of mycobacterial Eis proteins.

The multiple sequence alignment was performed with ENDscript$^{40}$ and adjusted manually. The secondary structure (α, α-helix; β, β-strand, η, 3$_{10}$-helix) of Eis$_{1\text{Mab}}$ extracted from its crystal structure, is indicated above the alignment. Residues involved in ACO binding in Eis$_{1\text{Mab}}$ are indicated by the green circles, residues involved in aminoglycoside recognition in $M.\text{tuberculosis}$ (Eis$_{\text{Mtb}}$) and $M.\text{smegmatis}$ (Eis$_{\text{Msm}}$) Eis are depicted by the black and cyan square respectively.

Figure 6: Structural comparison of Eis proteins reveals unique features in Eis$_{1\text{Mab}}$.

A Superposition of Eis crystal structures. All the structures are displayed as a ribbon representation with the following color codes: Eis$_{1\text{Mab}}$ in slate, Eis$_{\text{Mtb}}$ in yellow, Eis$_{2\text{Mab}}$ in raspberry, Eis$_{\text{Msm}}$ in magenta, Eis$_{\text{Ban}}$ in cyan, Eis$_{\text{Ava}}$ in orange, Eis$_{\text{Efa}}$ in salmon and Eis$_{\text{Kfl}}$ in red. Superposition of the carbon α was performed in Coot. The arrow indicates the loop between strands 9 and 10 which appears particularly extended in Eis$_{1\text{Mab}}$. B Comparison of the volume (grey surface area) of the active sites of the structures of Eis proteins that have been biochemically characterized, the color code is the same as in A. For structures solved with either ACO or CoA, the cofactor is shown as yellow sticks. C Key structural features restricting the size of the Eis$_{1\text{Mab}}$ (slate) substrate-binding pocket. Arrows highlight the helices α4 and α5 movements seen in Eis$_{1\text{Mab}}$ as compare with Eis$_{\text{Mtb}}$ (in yellow). Eis$_{1\text{Mab}}$ residues side chains that protrude towards the substrate binding-site are shown
as sticks and their equivalent residues in Eis\textsubscript{Mtb} that are not pointing towards the substrate pocket are also indicated.

**Figure 7: Comparison of the extended loop size and conformation**

**A** Close up at the interface of two Eis\textsubscript{Mab} monomers. The extended loop of monomer 2 in slate is covering the active site of monomer 1 (in white) and the Phe242 side chain is pointing towards the substrate-binding site of monomer 1 that is close to the ACO (stick representation) binding pocket. The superposition of Eis\textsubscript{Mtb} structure (PDB id: 4JD6) bound to tobramycin in yellow, to Eis\textsubscript{Mab} highlights the steric hindrance of Phe242, presumably preventing the binding of aminoglycosides. **B** Comparison of the same loop region with the one in other Eis crystal structures from various bacterial origins. Eis\textsubscript{Mtb} is in yellow, Eis\textsubscript{Msm} in magenta, Eis\textsubscript{Ban} in cyan and, Eis\textsubscript{Ava} in orange.
FIGURE 1
Figure 2
**FIGURE 3**

Panel A: Chemical structures of APRAMYCIN, HYGROMYCIN B, KANAMYCIN A, AMIKACIN, HISTAMINE, and TYRAMINE.

Panel B: Graph showing initial reaction rates with different compounds. The y-axis represents initial reaction rate (μM·s⁻¹), and the x-axis represents concentrations. The graph includes data points for APR_Eis1, HYG_Eis1, KAN_Eis1, ZEO_Eis1, Histamine_Eis1, Histamine_Eis2, and Tyramine_Eis1. The y-axis uses a scale from 0 to 2.0, and the x-axis uses scales of 0 to 200, 400, and 600. The reaction rates are indicated by bars with error bars. Significance levels are marked with asterisks (****).

Panel C: Scatter plots showing the relationship between initial reaction rates and [Tyramine] μM (left) and [Acetyl-CoA] μM (right). The R² values for these relationships are 98.4% and 98.1%, respectively. The graphs show the correlation between the concentration of the compounds and the initial reaction rates. The x-axes represent the concentrations, and the y-axes represent the initial reaction rates in μM·s⁻¹. The scatter plots include error bars indicating variability.
FIGURE 6
Supporting information Figure S1 : Generation of a Δeis2 M. abscessus mutant and Eis2 overexpressing strain.

A Schematic representation of the genomic region around eis2Mab in the parental (WT) and Δeis2Mab mutant strains of M. abscessus. Sizes of the PCR amplicons used for genotyping the Δeis2 mutant are shown. B PCR profile confirming the proper deletion of eis2Mab in the mutant strain. One PCR product of 1493 bp amplified from Δeis2Mab mutant genomic DNA is expected while one band at 2657 bp is expected for the WT strain. * Indicates an unspecific amplicon at about 1 kb, systematically obtained with these set of primers using the mutant or WT genomic DNA templates. The dashed lines indicate that two lanes were cropped from the gel. C Protein expression pattern of Eis2Mab in the parental (WT) and knockout strains. Western blotting using anti-Strep-tag primary antibodies attest for the expression of Eis2Mab in the two strains transformed with pMV261-Zeo-ets2 in three individual colonies (C1-C3). The strain transformed with the empty pMV261-Zeo was included as a negative control. The band at 70 kDa of the protein ladder possesses also a Strep-tag explaining its immune reactivity with the antibody.